Metropolis Healthcare Q2 Results: Can the Volume-Led Growth Streak Continue?

Updated: 24 Sept 2026 • 12:20 pm

Posted by:

Metropolis Healthcare Q2 Results: Can the Volume-Led Growth Streak Continue?

Metropolis Healthcare Q1 FY27 consolidated revenue Rs 450 crore (+16.6% YoY), consolidated PAT Rs 56.7 crore (+25.7% YoY). Q2 FY26 base: PAT Rs 53 crore (+13% YoY).

Quick Answer

Metropolis Healthcare's Q2 results FY27 date is not confirmed. Q1 FY27 (June 2026 quarter) consolidated net profit rose 25.72% YoY to Rs 56.7 crore on revenue of Rs 450 crore, up 16.58% YoY, with EBITDA margin expanding 145 basis points to 24.7% – growth achieved entirely through higher patient and test volumes without any price increases. The Q2 FY27 print will be compared against a Q2 FY26 base where profit had already grown 13% YoY to Rs 53 crore.

The Metropolis Healthcare Q2 results FY27 print is the next earnings event for India's second-largest pathology laboratory chain, which has been expanding into Tier 2 and Tier 3 cities through organic growth and acquisitions.

Click Here – Get Free Investment Predictions

Table of Contents

When Is the Metropolis Healthcare Q2 Results FY27 Date?

Not officially confirmed for the September 2026 quarter as of this writing. Q1 FY27 was reported August 10, 2026.

Metropolis Healthcare Q2 Results Expectations

No verified consensus estimate is available. Management has guided FY27 revenue growth of 14-16%, primarily volume-driven, with EBITDA margin improvement of 100-150 basis points targeted. Whether Q2 FY27 tracks that guidance, and whether specialty diagnostics (40% of Q1 FY27 revenue) keeps outgrowing the base business, are the things to watch.

Metropolis Healthcare Previous Quarter Performance (Q1 FY27)

Consolidated revenue Rs 450 crore (+16.58% YoY), EBITDA Rs 113 crore (+22-27% YoY) at a 24.7-25.2% margin, consolidated PAT Rs 56.7 crore (+25.72% YoY), EPS Rs 2.73. Patient volumes rose 10% to 3.7 million, test volumes 11% to 7.8 million. Specialty diagnostics contributed 40% of revenue (+17% YoY).

Metropolis Healthcare Q2 FY26 Base Quarter

Consolidated net profit Rs 53 crore, up 13% YoY, on 23% YoY consolidated revenue growth driven by preventive health check-up momentum.

Metropolis Healthcare Recent Quarterly Trend

Quarter	PAT (Rs Cr)
Q1 FY26	45.24
Q2 FY26	53
Q4 FY26	~40-50 (est.)
Q1 FY27	56.7

Key Factors That Could Shape Metropolis Healthcare Q2 Results FY27

Patient and test volume growth, the primary driver of results with no price hikes taken
Specialty diagnostics mix shift (40% of revenue), including oncology, genomics and women's health
TruHealth preventive wellness segment, contributing 18% of revenue and growing 22% YoY
Integration of recent acquisitions (DAPIC, Scientific Pathology) expanding North India presence

Metropolis Healthcare Q2 Results FY27: Valuation Going Into the Print

Metropolis Healthcare has historically commanded a premium diagnostics-sector multiple, trading in the Rs 500-550 range through mid-2026 on a debt-free balance sheet. No forward valuation is implied here, but the premium reflects the market pricing in continued double-digit, margin-accretive growth – which is exactly what Q1 FY27 delivered.

Download the Univest iOS App or Univest Android App to track Metropolis Healthcare live price and quarterly earnings updates.

What Investors Should Watch When Metropolis Healthcare Q2 Results Are Announced

Whether volume-led growth continues without price increases
Specialty diagnostics and TruHealth segment growth rates
EBITDA margin progress toward the 27-28% medium-term target

Conclusion on Metropolis Healthcare Q2 Results FY27

Metropolis Healthcare's Q2 FY27 print will be watched for continued volume-led, price-hike-free growth against a Q2 FY26 base of Rs 53 crore PAT, itself already up 13% YoY.

Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).